Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment To Prevent Fractures in Men and Women With Low Bone Density or Osteoporosis: An Update

Slide: 29 of 40

Adverse Effects of Medications for Low Bone Density or Osteoporosis (2 of 3)

Raloxifene is associated with pulmonary embolism. The likelihood is 5.27-fold that of untreated groups, and the statistically valid range for the association is from 1.29- to 46.4-fold. The strength of evidence for this finding is high.

Raloxifene is associated with thromboembolic events. The likelihood is 1.63-fold that of untreated groups, and the statistically valid range for the association is from 1.36- to 1.98-fold. The strength of evidence for this finding is high.

Raloxifene is associated with myalgias, cramps, and limb pain. The likelihood is 1.53-fold that of untreated groups, and the statistically valid range for the association is from 1.29- to 1.81-fold. The strength of evidence for this finding is high.

Raloxifene is associated with hot flashes. The likelihood is 1.58-fold that of untreated groups, and the statistically valid range for the association is from 1.35- to 1.84-fold. The strength of evidence for this finding is high.

Teriparatide is associated with hypercalcemia and headaches. The likelihood of hypercalcemia is 12.9-fold that of untreated groups. The statistically valid range for the association is from 10.49- to 16-fold. The strength of evidence for this finding is moderate. The likelihood of headaches is 1.44-fold that of untreated groups. The statistically valid range for the association is from 1.24- to 1.67-fold. The strength of evidence for this finding is moderate.

Denosumab is associated with mild GI events, rashes, and infections. The likelihood of GI events is 2.13-fold that of untreated groups. The statistically valid range for the association is from 1.11- to 4.4-fold. The strength of evidence for this finding is moderate. The likelihood of rashes is 2.01-fold that of untreated groups. The statistically valid range for the association is from 1.5- to 2.73-fold. The strength of evidence for this finding is high. The likelihood of infection is 1.28-fold that of untreated groups. The statistically valid range for the association is from 1.02- to 1.60-fold. The strength of evidence for this finding is high.